

Article

Synthesis and In Vitro Biological Studies of Heterocyclic Benzimidazole Derivatives as Potential Therapeutics for Trichinellosis

Kameliya Anichina ¹, Galya Popova-Daskalova ², Dimitar Vuchev ², Maya Guncheva ³, Denitsa Yancheva ^{1,3} and Nikolai Georgiev ^{1,*}

¹ Department of Organic Synthesis, University of Chemical Technology and Metallurgy, 8 Kliment Ohridski Blvd., 1756 Sofia, Bulgaria; kameliya_anichina@uctm.edu

² Department of Infectious Diseases, Parasitology and Tropical Medicine, Medical University, 4000 Plovdiv, Bulgaria; galiya.popova@mu-plovdiv.bg (G.P.-D.); dimitar.vuchev@mu-plovdiv.bg (D.V.)

³ Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, Acad. G. Bonchev str. Bl. 9, 1113 Sofia, Bulgaria; Maya.Guncheva@orgchm.bas.bg (M.G.); Denitsa.Pantaleeva@orgchm.bas.bg (D.Y.)

* Correspondence: nikigeorgiev@uctm.edu


Contents

Figures. S1-S17. IR, NMR and HRMS (ESI) spectra of the synthesized compounds

.....
..... pages 2-10

Figures S18-S24. Bioavailability-radars computed by the SwissADME web-tool for the synthesized compounds and albendazole
pages 11-14

Figure S25. Tubulin (final 54 μ M) in the presence of 10 μ M of compounds 6a (a), and 6b (b)..... page 15



D:\Niki\IR\Anichina\KA-324.0

KA-324

ATR

14.4.2025 a

Fig. S1. IR spectrum of compound 4a.




Fig. S2. ¹H NMR spectrum of compound 4a.

Fig. S3. HRMS (ESI) spectrum of compound 4a.



Page 1/1

Fig. S4. IR spectrum of compound 4b.





Fig. S5. HRMS (ESI) spectrum of compound 4b.



Page 1/1

Fig. S6. IR spectrum of compound 4c.







Fig. S7. ^1H NMR spectrum of compound 4c.Fig. S8. ^{13}C NMR spectrum of compound 4c.

Fig. S9. HRMS (ESI) spectrum of compound 4c.






Fig. S12. HSQC spectrum of compound 6a




Fig. S13. HRMS (ESI) spectrum of compound 6a.



Fig. S14. ^1H NMR spectrum of compound 6b.

Fig. S15. HRMS (ESI) spectrum of compound 6b.



Fig. S16. ^1H NMR spectrum of compound 6c.

Fig. S17. HRMS (ESI) spectrum of compound 6c.




Fig. S18. Bioavailability-radar computed by the SwissADME web-tool for compound 4a.




Fig. S19. Bioavailability-radar computed by the SwissADME web-tool for compound 4b.




Fig. S20. Bioavailability-radar computed by the SwissADME web-tool for compound 4c.




Fig. S21. Bioavailability-radar computed by the SwissADME web-tool for compound 6a.




Fig. S22 Bioavailability-radar computed by the SwissADME web-tool for compound 6b.




Fig. S23. Bioavailability-radar computed by the SwissADME web-tool for compound 6c.






Fig. S24. Bioavailability-radar computed by the SwissADME web-tool for Albendazole.



a)



b)

Figure S25. Tubulin (final 54 μ M) in the presence of 10 μ M of compounds 6a (a), and 6b (b).